Company profile: Exosome Diagnostics
1.1 - Company Overview
Company description
- Provider of biofluid-based molecular diagnostics leveraging exosome-derived nucleic acids for personalized medicine, including the urine-based, non-invasive ExoDx Prostate Test that provides a risk score for high-grade prostate cancer using genomic biomarkers from urine exosomes, plus at-home and in-office collection kits, EMR integrations, and availability for U.S. Veterans, supporting patient stratification and disease monitoring.
Products and services
- ExoDx Prostate Test: Non-invasive diagnostic that yields a risk score for high-grade prostate cancer by analyzing genomic biomarkers contained in urine exosomes collected via simple urine sample
- EMR Integrations: EMR-integrated service that streamlines ordering and result management of the ExoDx Prostate Test within electronic medical records systems
- At-Home Collection Kit: At-home kit enabling patients to collect urine samples for the ExoDx Prostate Test without an office visit, facilitating remote urine collection for the urine-exosome biomarker assessment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Exosome Diagnostics
Vivet Therapeutics
HQ: France
Website
- Description: Provider of AAV-based gene therapies for orphan diseases, including VTX-801 for Wilson’s disease, VTX-802 for Progressive Familial Intrahepatic Cholestasis Type 2, VTX-803 for Progressive Familial Intrahepatic Cholestasis Type 3, VTX-804 for Citrullinemia Type 1, and VTX-806 for Cerebrotendinous Xanthomatosis, plus VTX-PSM, a non-integrative viral technology for sustainable transgene expression, partnered with FIMA/CIMA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivet Therapeutics company profile →
InKaryo
HQ: United States
Website
- Description: Provider of cytogenetic analysis services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InKaryo company profile →
4D Lifetec
HQ: Switzerland
Website
- Description: Provider of molecular diagnostic screening and test systems, including DNA defect and repair-based screening programs, and non-invasive immuno-oncological blood tests for early cancer detection. Offers 4D Lifetest to detect stages I and II via DNA fragmentation using the DDS biomarker, and 4D Lifetest Lung Dx for early-stage lung cancer, reducing invasive procedures and guiding treatment paths.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Lifetec company profile →
Guardant Health
HQ: United States
Website
- Description: Provider of precision oncology diagnostics, including Shield, an FDA-approved blood test for colorectal cancer screening; Guardant Reveal for MRD in early-stage cancers; Guardant360 CDx, an FDA-approved liquid biopsy for comprehensive genomic profiling in advanced solid tumors; Guardant360 Response for treatment monitoring; Guardant360 TissueNext with AI-powered PD-L1 detection; and Guardant Infinity for biomarker discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Guardant Health company profile →
Color Health
HQ: United States
Website
- Description: Provider of a healthcare delivery platform offering clinical-grade genetic testing for cancer and heart risk, cancer care management, cardiometabolic care, and COVID-19 testing, vaccination, and treatment with telehealth and prescription delivery, plus a research platform with genetic sequencing, bioinformatics, and participant engagement for large-scale health initiatives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Color Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Exosome Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Exosome Diagnostics
2.2 - Growth funds investing in similar companies to Exosome Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Exosome Diagnostics
4.2 - Public trading comparable groups for Exosome Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →